Abstract:ABSTRACT Introduction Patients with type 2 diabetes mellitus (T2DM) are at risk for a variety of severe debilitating effects. One of the most serious complications experienced by T2DM patients are skeletal diseases caused by changes in the bone microenvironment. As a result, T2DM patients are at risk for higher prevalence of fragility fractures. There are a variety of treatments available for counteracting this effect. Some anti-diabetic medications, such as metformin, have been shown to have a positive effect on bone health without the addition of additional drugs into patients’ treatment plans. Chinese randomized controlled trial (RCT) studies have also proposed antiresorptive pharmacotherapies as a viable alternative treatment strategy. Previous network meta-analyses (NMAs) and meta-analyses regarding this topic did not include all available RCT trials, or only performed pairwise comparisons. We present a protocol for a two-part NMA that incorporates all available RCT data to provide the most comprehensive ranking of anti-diabetics (Part I) and antiresorptive (Part II) pharmacotherapies in terms of their ability to decrease fracture incidences, increase bone mineral density (BMD), improve indications of bone turnover markers (BTMs), and decrease pain in adult T2DM patients. Methods and Analysis We will search MEDLINE, EMBASE, PubMed, Web of Science, CINAHL, CENTRAL and Chinese literature sources (CNKI, CQVIP, Wanfang Data, Wanfang Med Online) for randomized controlled trials (RCTs) which fit our criteria. We will include adult T2DM patients who have taken anti-diabetics (Part I) or antiresorptive (Part II) therapies with relevant outcome measures in our study. We will perform title/abstract and full-text screening as well as data extraction in duplicate. Risk of bias (RoB) will be evaluated in duplicate for each study, and the quality of evidence will be examined using CINeMA in accordance to the GRADE framework. We will use R and gemtc to perform the NMA. We will report changes in BMD, BTM and pain scores in either weighted or standardized mean difference, and we will report fracture incidences as odds ratios. We will use the surface under the cumulative ranking curve (SUCRA) scores to provide numerical estimates of the rankings of interventions. Ethics and Dissemination The study will not require ethics approval. The findings of the two-part NMA will be disseminated in peer-reviewed journals and presented at conferences. We aim to produce the most comprehensive quantitative analysis regarding the management of T2DM bone disease. Our analysis should be able to provide physicians and patients with up-to-date recommendations for anti-diabetic medications and antiresorptive pharmacotherapies for maintaining bone health in T2DM patients. Systematic Review Registration International Prospective Register for Systematic Reviews (PROSPERO) — CRD42019139320 ARTICLE SUMMARY Strengths and limitations of this study Literature search in Chinese databases will yield new RCT evidence regarding the efficacy of anti-diabetics in treating T2DM bone disease Using network meta-analytical techniques to analyze the relative efficacy of antiresorptive therapies will allow us to include new treatment arms, such as zoledronic acid and risedronate. Only RCTs will be included and the quality of trials and networks will be evaluated using Risk of Bias, GRADE and comparison-adjusted funnel plots. Chinese clinicians may not use the same procedures and practices as Western clinicians, therefore the outcomes from Chinese RCTs may not apply to the Western healthcare systems. The study design does not allow the comparison of anti-diabetics with antiresorptive therapies or combinations of the two.

Chinese expert consensus on the management of fracture risk in diabetic patients

Management of Fracture Risk in Patients with Diabetes-Chinese Expert Consensus

Bone metabolism in diabetes: a clinician's guide to understanding the bone–glucose interplay

Potential Metabolic Pathways Involved in Osteoporosis and Evaluation of Fracture Risk in Individuals with Diabetes

Bone Fragility in Diabetes and its Management: A Narrative Review

Bone health in diabetes and prediabetes

Bone disorders associated with diabetes mellitus and its treatments

Advanced glycation end products mediate biomineralization disorder in diabetic bone disease

Expert consensus on Prospective Precision Diagnosis and Treatment Strategies for Osteoporotic Fractures

Anti-Diabetic and Antiresorptive Pharmacotherapies for Prevention and Treatment of Type 2 Diabetes-Induced Bone Disease: Protocol for a Two-Part Systematic Review and Network Meta-Analysis

Osteoporosis and diabetes - possible links and diagnostic difficulties

Attention is needed to bone fragility in patients with type 2 diabetes mellitus

Chinese Expert Consensus on the Diagnosis of Osteoporosis by Imaging and Bone Mineral Density

Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition)

Major Osteoporosis Fracture Prediction in Type 2 Diabetes: a Derivation and Comparison Study

Bone Health in Patients With Type 2 Diabetes

Diabetes and bone health: latest evidence and clinical implications

Hip fracture is associated with a reduced risk of type 2 diabetes: A retrospective cohort study

Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions

Recent progress in bone-repair strategies in diabetic conditions

Expert consensus on the bone repair strategy for osteoporotic fractures in China